Pages that link to "Q40389351"
Jump to navigation
Jump to search
The following pages link to Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. (Q40389351):
Displaying 50 items.
- Follicular lymphoma: 2012 update on diagnosis and management (Q22252956) (← links)
- Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity (Q26773135) (← links)
- Follicular lymphoma: 2011 update on diagnosis and management (Q26851450) (← links)
- Follicular lymphoma: 2014 update on diagnosis and management (Q27021850) (← links)
- New antibody approaches to lymphoma therapy (Q27022373) (← links)
- Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development (Q27693252) (← links)
- Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies (Q27694769) (← links)
- Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions (Q28269136) (← links)
- Novel CD20 monoclonal antibodies for lymphoma therapy (Q28390112) (← links)
- Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects (Q33388543) (← links)
- Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study (Q33408915) (← links)
- Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia (Q33434522) (← links)
- Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides (Q33645793) (← links)
- Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data (Q33685903) (← links)
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity (Q33896738) (← links)
- Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs (Q34011214) (← links)
- Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. (Q34440110) (← links)
- Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (Q34463593) (← links)
- The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (Q34470502) (← links)
- Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. (Q34750560) (← links)
- Rituximab resistance (Q35041270) (← links)
- A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 indolent NHL: correlation between clinical responses and AUC pharmacokinetics (Q35142620) (← links)
- Targeted treatment for chronic lymphocytic leukemia (Q35599741) (← links)
- Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL. (Q35760142) (← links)
- Novel targeted therapies for mantle cell lymphoma (Q35889841) (← links)
- Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies (Q37178611) (← links)
- B-lymphocyte depletion with rituximab and β-cell function: two-year results (Q37504134) (← links)
- Emerging therapies for B-cell non-Hodgkin lymphoma (Q37598947) (← links)
- Anti-CD20 monoclonal antibodies: historical and future perspectives (Q37601775) (← links)
- Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia (Q37613872) (← links)
- Investigational immunotherapeutics for B-cell malignancies (Q37667386) (← links)
- Evolution of anti-CD20 monoclonal antibody therapeutics in oncology (Q37676785) (← links)
- Novel agents for B-cell non-Hodgkin lymphoma: science and the promise (Q37691759) (← links)
- The future of CD20 monoclonal antibody therapy in B-cell malignancies (Q37724396) (← links)
- Targeted treatment and new agents in diffuse large B cell lymphoma (Q37766121) (← links)
- Targeted treatment and new agents in follicular lymphoma (Q37767367) (← links)
- Diversity in antibody-based approaches to non-Hodgkin lymphoma (Q37785097) (← links)
- New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma (Q37786616) (← links)
- New drugs for aggressive B-cell and T-cell lymphomas (Q37807160) (← links)
- New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies (Q37810901) (← links)
- Molecular Target Therapy in Hematological Malignancy: Front-runners and Prototypes of Small Molecule and Antibody Therapy (Q37813006) (← links)
- Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies (Q37842484) (← links)
- New antibody drug treatments for lymphoma (Q37852003) (← links)
- Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results (Q37863985) (← links)
- Non-MALT marginal zone lymphoma (Q37876154) (← links)
- Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. (Q37884384) (← links)
- Novel antibodies against follicular non-Hodgkin’s lymphoma (Q37887147) (← links)
- Update on Novel Monoclonal Antibodies anD Immunoconjugates for the Treatment of Lymphoproliferative Disorders (Q37913356) (← links)
- The future role of monoclonal antibody therapy in childhood acute leukaemias (Q38033600) (← links)
- Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia (Q38068494) (← links)